Endothelial loss and repair in the vascular complications of diabetes - Pmechanisms and therapeutic implications -

Circulation Journal

Volumn 77, Issue 4, 2013, Pages 849-856

  Gilbert, Richard E ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Diabetes mellitus; Endothelium; Kidney

Indexed keywords

CASPASE 3; CD133 ANTIGEN; CD146 ANTIGEN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; IRBESARTAN; LIPOPROTEIN; OLMESARTAN; PLERIXAFOR; PROTEIN P53; SILENT INFORMATION REGULATOR PROTEIN; SITAGLIPTIN; STROMAL CELL DERIVED FACTOR 1; TELMISARTAN; VASCULAR ENDOTHELIAL CADHERIN;

ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROSIS; CARDIOMYOPATHY; CELL DEATH; CELL MIGRATION; CELL REGENERATION; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC RETINOPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; HUMAN; KIDNEY DISEASE; META ANALYSIS (TOPIC); MICROANGIOPATHY; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENESCENCE; STEM CELL MOBILIZATION; VASCULAR DISEASE;

ARTERIES; ATHEROSCLEROSIS; CELL DEATH; DIABETIC ANGIOPATHIES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS;

EID: 84875499076     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0236     Document Type: Review

References (64)

1. McClung JA, Naseer N, Saleem M, Rossi GP, Weiss MB, Abraham NG, et al. Circulating endothelial cells are elevated in patients with type 2 diabetes mellitus independently of HbA1c. Diabetologia 2005; 48: 345-350.
2. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: Two sides of the coin. Physiology 2005; 20: 22-27.
3. Koga H, Sugiyama S, Kugiyama K, Watanabe K, Fukushima H, Tanaka T, et al. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2005; 45: 1622-1630.
4. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180: 1332-1339.
5. Alter DA, Khaykin Y, Austin PC, Tu JV, Hux JE. Processes and outcomes of care for diabetic acute myocardial infarction patients in Ontario: Do physicians undertreat? Diabetes Care 2003; 26: 1427-1434.
6. Woodfield SL, Lundergan CF, Reiner JS, Greenhouse SW, Thompson MA, Rohrbeck SC, et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: The GUSTO-I experience. J Am Coll Cardiol 1996; 28: 1661-1669.
7. Henriques JP, Zijlstra F, van't Hof AW, de Boer MJ, Dambrink JH, Gosselink M, et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 2003; 107: 2115-2119.
8. Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, et al; Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris (EMERALD) Investigators. Distal microcirculatory protection during percutaneous coronary intervention in acute STsegment elevation myocardial infarction: A randomized controlled trial. JAMA 2005; 293: 1063-1072.
9. Boodhwani M, Sodha NR, Mieno S, Xu SH, Feng J, Ramlawi B, et al. Functional, cellular, and molecular characterization of the angiogenic response to chronic myocardial ischemia in diabetes. Circulation 2007; 116: I31-I37.
10. Marwick TH. Diabetic heart disease. Heart 2006; 92: 296-300.
11. Rakusan K, Flanagan MF, Geva T, Southern J, Van Praagh R. Morphometry of human coronary capillaries during normal growth and the effect of age in left ventricular pressure-overload hypertrophy. Circulation 1992; 86: 38-46.
12. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, et al. Myocardial cell death in human diabetes. Circ Res 2000; 87: 1123-1132.
13. Mauer SM. Structural-functional correlations of diabetic nephropathy. Kidney Int 1994; 45: 612-622.
14. Fine LG, Bandyopadhay D, Norman JT. Is there a common mecha nism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl 2000; 75: S22-S26.
15. Caplan BA, Schwartz CJ. Increased endothelial cell turnover in areas of in vivo evans blue uptake in the pig aorta. Atherosclerosis 1973; 17: 401-417.
16. Aoki M, Nata T, Morishita R, Matsushita H, Nakagami H, Yamamoto K, et al. Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: Antiapoptotic effect of antioxidant agents on endothelial cells. Hypertension 2001; 38: 48-55.
17. Nakagami H, Morishita R, Yamamoto K, Yoshimura SI, Taniyama Y, Aoki M, et al. Phosphorylation of p38 mitogen-activated protein kinase downstream of bax-caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells. Diabetes 2001; 50: 1472-1481.
18. Ho FM, Lin WW, Chen BC, Chao CM, Yang CR, Lin LY, et al. High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway. Cellular Signalling 2006; 18: 391-399.
19. Orimo M, Minamino T, Miyauchi H, Tateno K, Okada S, Moriya J, et al. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler Thromb Vasc Biol 2009; 29: 889-894.
20. Michan S, Sinclair D. Sirtuins in mammals: Insights into their biological function. Biochem J 2007; 404: 1-13.
21. Dimmeler S, Haendeler J, Zeiher AM. Regulation of endothelial cell apoptosis in atherothrombosis. Curr Opin Lipidol 2002; 13: 531-536.
22. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
23. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 288-293.
24. Urbich C, De Souza AI, Rossig L, Yin X, Xing Q, Prokopi M, et al. Proteomic characterization of human early pro-angiogenic cells. J Mol Cell Cardiol 2011; 50: 333-336.
25. Yoder MC. Human endothelial progenitor cells. Cold Spring Harb Perspect Med 2012; 2: a006692.
26. Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, Dzau VJ. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol 2011; 50: 280-289.
27. Yuen DA, Connelly KA, Advani A, Liao C, Kuliszewski MA, Trogadis J, et al. Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism. PLoS One 2010; 5: e9543.
28. Zhang Y, Yuen DA, Advani A, Thai K, Advani SL, Kepecs D, et al. Early-outgrowth bone marrow cells attenuate renal injury and dysfunction via an antioxidant effect in a mouse model of type 2 diabetes. Diabetes 2012; 61: 2114-2125.
29. Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): Controversies, myths, and changing paradigms. Mol Ther 2009; 17: 939-946.
30. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
31. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007.
32. Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005; 45: 1449-1457.
33. Fadini GP, Boscaro E, de Kreutzenberg S, Agostini C, Seeger F, Dimmeler S, et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care 2010; 33: 1097-1102.
34. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, et al. Endothelial progenitor cell dysfunction: A novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004; 53: 195-199.
35. Kusuyama T, Omura T, Nishiya D, Enomoto S, Matsumoto R, Takeuchi K, et al. Effects of treatment for diabetes mellitus on circulating vascular progenitor cells. J Pharmacol Sci 2006; 102: 96-102.
36. Boyle AJ, Whitbourn R, Schlicht S, Krum H, Kocher A, Nandurkar H, et al. Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: A 12-month follow-up. Int J Cardiol 2006; 109: 21-27.
37. Busik JV, Tikhonenko M, Bhatwadekar A, Opreanu M, Yakubova N, Caballero S, et al. Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. J Exp Med 2009; 206: 2897-2906.
38. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, et al. HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest 2001; 108: 399-405.
39. Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, et al. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 2004; 109: 220-226.
40. Jaumdally RJ, Goon PK, Varma C, Blann AD, Lip GY. Effects of atorvastatin on circulating CD34+/CD133+/CD45-progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus. J Intern Med 2010; 267: 385-393.
41. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-864.
42. Proost P, Struyf S, Schols D, Durinx C, Wuyts A, Lenaerts JP, et al. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett 1998; 432: 73-76.
43. Segal MS, Shah R, Afzal A, Perrault CM, Chang K, Schuler A, et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes 2006; 55: 102-109.
44. Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M, et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and-independent actions. Circulation 2012; 126: 1838-1851.
45. Yuen DA, Zhang Y, Thai K, Spring C, Chan L, Guo X, et al. Angiogenic dysfunction in bone marrow-derived early outgrowth cells from diabetic animals is attenuated by SIRT1 activation. Stem Cells Transl Med 2012; 1: 921-926.
46. Brunner S, Schernthaner GH, Satler M, Elhenicky M, Hoellerl F, Schmid-Kubista KE, et al. Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy: First in vivo data. Invest Ophthalmol Vis Sci 2009; 50: 392-398.
47. Martinet W, Schrijvers DM, De Meyer GR. Pharmacological modulation of cell death in atherosclerosis: A promising approach towards plaque stabilization? Br J Pharmacol 2011; 164: 1-13.
48. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, et al. Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis. Arch Intern Med 2007; 167: 989-997.
49. Jeevanantham V, Butler M, Saad A, Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: A systematic review and meta-analysis. Circulation 2012; 126: 551-568.
50. Endtmann C, Ebrahimian T, Czech T, Arfa O, Laufs U, Fritz M, et al. Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: Implications for vascular regeneration. Hy pertension 2011; 58: 394-403.
51. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: A new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 2005; 45: 526-529.
52. Aoki A, Murata M, Asano T, Ikoma A, Sasaki M, Saito T, et al. Prompt increases in retinol-binding protein 4 and endothelial progenitor cells during acute exercise load in diabetic subjects. Endocr J 2012; 59: 1085-1091.
53. Takahashi M. Role of the SDF-1/CXCR4 system in myocardial infarction. Circ J 2010; 74: 418-423.
54. Unoki N, Murakami T, Nishijima K, Ogino K, van Rooijen N, Yoshimura N. SDF-1/CXCR4 contributes to the activation of tip cells and microglia in retinal angiogenesis. Invest Ophthalmol Vis Sci 2010; 51: 3362-3371.
55. Saxena A, Fish JE, White MD, Yu S, Smyth JW, Shaw RM, et al. Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation 2008; 117: 2224-2231.
56. Hiesinger W, Perez-Aguilar JM, Atluri P, Marotta NA, Frederick JR, Fitzpatrick III JR, et al. Computational protein design to reengineer stromal cell-derived factor-1α generates an effective and translatable angiogenic polypeptide analog Circulation 2011; 124: S18-S26.
57. Segers VF, Tokunou T, Higgins LJ, MacGillivray C, Gannon J, Lee RT. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007; 116: 1683-1692.
58. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004; 110: 3300-3305.
59. Zaruba MM, Theiss HD, Vallaster M, Mehl U, Brunner S, David R, et al. Synergy between CD26/DPP-IV inhibition and g-csf improves cardiac function after acute myocardial infarction. Cell Stem Cell 2009; 4: 313-323.
60. Connelly K, Zhang Y, Advani A, Advani S, Thai K, Yuen D, et al. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodelling following myocardial infarction in rats with experimental diabetes. Cardiovasc Ther 2012 September 11, doi:10.1111/1755-5922.12005 [Epub ahead of print].
61. Huang CY, Shih CM, Tsao NW, Lin YW, Huang PH, Wu SC, et al. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br J Pharmacol 2012; 167: 1506-1519.
62. Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: Possible role of stromal-derived factor-1alpha. Diabetes Care 2010; 33: 1607-1609.
63. Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013; 15: 112-120.
64. Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. Circ J 2011; 75: 2739-2748.